Abbott Laboratories $ABT Shares Acquired by Guyasuta Investment Advisors Inc.

Guyasuta Investment Advisors Inc. lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 22.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 27,451 shares of the healthcare product maker’s stock after purchasing an additional 5,002 shares during the period. Guyasuta Investment Advisors Inc.’s holdings in Abbott Laboratories were worth $3,439,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth $27,000. Cloud Capital Management LLC purchased a new position in Abbott Laboratories in the third quarter valued at about $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories in the third quarter valued at about $31,000. Delos Wealth Advisors LLC purchased a new position in Abbott Laboratories in the second quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories in the third quarter valued at about $33,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $100.17 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a one year low of $99.34 and a one year high of $139.06. The company’s 50-day simple moving average is $108.92 and its 200-day simple moving average is $119.76. The stock has a market capitalization of $174.46 billion, a price-to-earnings ratio of 26.93, a PEG ratio of 1.60 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter last year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: TD Cowen reiterated a Buy on ABT and kept a $137 price target, citing a resilient MedTech and diagnostics mix that supports Abbott’s path to 2026 targets. TipRanks: TD Cowen Note
• Positive Sentiment: Citi recently initiated/maintained a Buy on ABT (coverage note reported), providing analyst support that can limit downside from headline risk. Globe & Mail: Citi Buy
• Positive Sentiment: Recent coverage highlighting Abbott as a dividend-king value/attractive yield may draw income-focused buyers who view current weakness as a buying opportunity. MarketBeat: Dividend King
• Neutral Sentiment: Abbott published consumer survey PR on chronic disease prevention (brand/marketing relevance). Useful for positioning but unlikely to move the stock materially in the short term. PR Newswire: Survey
• Neutral Sentiment: Wall Street previews note mixed expectations ahead of upcoming earnings (EPS growth expected but edge cases for a beat are limited), so the report could produce volatility but not a clear directional catalyst yet. Yahoo: Earnings Preview
• Negative Sentiment: A Chicago jury ordered Abbott to pay $53 million in compensatory damages in a preterm infant formula trial — a headline legal loss that raises litigation risk and investor concern about reputational and settlement exposure. Reuters: Jury Verdict
• Negative Sentiment: Short interest rose sharply in March (up ~19.4% vs. mid‑March), bringing total shorted shares to ~23.8M and a ~1.6 days-to-cover — increased bearish positioning can amplify downward moves on negative headlines.
• Negative Sentiment: Evercore trimmed its price target (reported) and broader healthcare stocks were weaker today, adding sector pressure; analyst and macro pressure can compound headline-driven selling. American Banking News: Evercore PT Cut

Insider Buying and Selling at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $102,288.30. Following the transaction, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP John A. Jr. Mccoy sold 585 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares in the company, valued at $2,846,504.24. This represents a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on ABT. Sanford C. Bernstein cut their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Citigroup cut their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Leerink Partners cut their price objective on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Weiss Ratings lowered Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 26th. Finally, Raymond James Financial cut their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $134.58.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.